Activating efficiency of Ca2+ and cross-bridges as measured by phosphate analog release.
To assess the activating efficiency of Ca2+ and cross-bridges, the release rates of phosphate analogs from skinned fibers were estimated from the recovery of contractility and that of stiffness. Estimations were performed based on the assumptions that contractility was indicative of the population of analog-free myosin heads and that stiffness reflected the population of formed cross-bridges. Aluminofluoride (AlFx) and orthovanadate (Vi) were used as phosphate analogs with mechanically skinned fibers from rabbit psoas muscle. The use of the analogs enabled the functional assessment of activation level in the total absence of ATP. Fibers loaded with the analogs gradually recovered contractility and stiffness in normal plain rigor solution. The addition of Ca2+ to the plain rigor solution significantly accelerated their recovery, whereas ADP had no appreciable effect. ATP plus Ca2+(contracting condition) accelerated the recovery by several tens of times. These results indicate that the cross-bridges formed during contraction have prominent activating efficiency, which is indispensable to attain full activation. A comparison between the activating efficiency evaluated from stiffness and that from contractility suggested that Ca2+ is more potent in accelerating the binding of actin to analog-bound myosin heads whereas cross-bridges mainly accelerate the subsequent analog-releasing step.
Yamaguchi
M
M
Department of Physiology, The Jikei University School of Medicine, Minato-ku, Tokyo 105-8461, Japan. maki@jikei.ac.jp
Takemori
S
S
D000199:Actins / Q000378:metabolism; D000244:Adenosine Diphosphate / Q000378:metabolism / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000378:metabolism / Q000494:pharmacology; D017607:Aluminum Compounds / Q000378:metabolism; D000818:Animals; D055592:Biophysical Phenomena; D001703:Biophysics; D002118:Calcium / Q000378:metabolism* / Q000494:pharmacology; D005459:Fluorides / Q000378:metabolism; D066298:In Vitro Techniques; D009119:Muscle Contraction / Q000187:drug effects / Q000502:physiology; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism*; D009218:Myosins / Q000378:metabolism; D011817:Rabbits; D014638:Vanadates / Q000378:metabolism
D000199:Actins; D017607:Aluminum Compounds; D014638:Vanadates; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D009218:Myosins; D005459:Fluorides; D002118:Calcium; C032311:aluminum fluoride